

15 October 2019

## ASX ANNOUNCEMENT

### **CLARIFICATION: ADMEDUS INKS \$A36.2M DEAL FOR CARDIOCEL® AND VASCUCEL® PATCH BUSINESS**

Admedus Limited (AHZ or the Company) provides the following clarification in relation to the \$22.8M upfront payment for the sale of its CardioCel® and VascuCel® patch business to U.S based LeMaitre Vascular Inc. (NASDAQ: LMAT, 'LeMaitre'). The A\$22.8M consideration is exclusive of the two instalments of \$A1m but does reflect the proceeds to be paid by LeMaitre on delivery of stock ordered on completion of the transaction. The cash received by the Company on the completion date was A\$21.2M.

**ENDS**

#### **About Admedus Limited (ASX: AHZ)**

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

#### **For more information:**

[Admedus@we-buchan.com](mailto:Admedus@we-buchan.com)

[www.admedus.com](http://www.admedus.com)

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](https://www.facebook.com/pages/Admedus)

#### **Admedus Limited**

##### **Registered Office:**

Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

##### **Customer Service:**

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: [info@admedus.com](mailto:info@admedus.com) W: [admedus.com](http://admedus.com)

